VEGFR2-IN-84 是一种基于萘环骨架、口服有效的多靶点酪氨酸激酶抑制剂,能够以亚纳摩尔级别的亲和力抑制 VEGFR2,并广泛靶向 Kit、FGFR、PDGFR 及 Ret 等激酶,通过竞争性结合 ATP 结合口袋阻断 VEGFR2 及其下游 AKT/ERK 信号通路的磷酸化,从而显著抑制内皮细胞增殖、迁移及肿瘤血管生成,对肝癌、肺癌、肾癌等多种实体瘤具有广谱抗增殖活性,且对正常细胞毒性较弱,效力优于 Lenvatinib (MS-K83330),并具有良好的药代动力学特征和较高的安全性 (LD50>2000 mg/kg),可用于多种恶性肿瘤的相关研究。
产品编号: MS-U35744 CAS No.: 861877-12-5 分子式: C25H18N4O4S 分子量: 470.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

VEGFR2-IN-84 是一种基于萘环骨架、口服有效的多靶点酪氨酸激酶抑制剂,能够以亚纳摩尔级别的亲和力抑制 VEGFR2,并广泛靶向 Kit、FGFR、PDGFR 及 Ret 等激酶,通过竞争性结合 ATP 结合口袋阻断 VEGFR2 及其下游 AKT/ERK 信号通路的磷酸化,从而显著抑制内皮细胞增殖、迁移及肿瘤血管生成,对肝癌、肺癌、肾癌等多种实体瘤具有广谱抗增殖活性,且对正常细胞毒性较弱,效力优于 Lenvatinib (MS-K83330),并具有良好的药代动力学特征和较高的安全性 (LD50>2000 mg/kg),可用于多种恶性肿瘤的相关研究。

生物实验数据

生物活性 VEGFR2-IN-84 is an orally active, multi-target tyrosine kinase inhibitor based on a naphthalene scaffold that inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret; by competitively binding to the ATP-binding pocket, it blocks phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathways, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis, and it exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and kidney cancer with weak toxicity to normal cells and greater potency than Lenvatinib (MS-K83330), while also possessing favorable pharmacokinetic properties and high safety (LD50>2000 mg/kg), making it suitable for research on various malignant tumors.
IC50 & Target VEGFR2:0.303 nM (EC50)
体外研究
(In Vitro)

VEGFR2-IN-84 (E20) (4.92 nM;96 h) 显著抑制 VEGF 诱导的 HUVEC 细胞增殖,活性约为 Lenvatinib (MS-K83330) 的 10 倍。
VEGFR2-IN-84 (10-1000 nM;48 h) 剂量依赖性地抑制 HUVEC、A549 和 HepG2 细胞中 VEGFR2 及其下游 AKT、ERK 的磷酸化,且活性优于 Lenvatinib。
VEGFR2-IN-84 (8.53-14.1 μM;72 h) 对正常细胞 LO2、HEK293T 和 BEAS-2B 的抑制活性较弱,显示出良好的肿瘤细胞选择性。

Cell Proliferation Assay

Cell Line: Human umbilical vein endothelial cells (HUVECs)
Concentration: IC50
Incubation Time: 96 h
Result: Significantly inhibited hVEGF-165 (20 ng/mL)-induced proliferation of HUVECs with an IC50 value of 4.92 nM, which was over 10-fold more potent than lenvatinib (IC50=51.2 nM).

Western Blot Analysis

Cell Line: HUVECs, A549 cells, HepG2 cells
Concentration: 10 nM, 1000 nM
Incubation Time: 48 h
Result: Dose-dependently suppressed hVEGF-165 (50 ng/mL)-induced phosphorylation of VEGFR2 (Tyr1175), AKT (Ser473), and ERK1/2 (Thr202/Tyr204) in HUVECs.
Significantly reduced p-VEGFR2 and p-ERK levels.
Dose-dependently inhibited the phosphorylation of VEGFR2, AKT, and ERK in A549 and HepG2 cells, and exhibited more potent inhibitory effects than lenvatinib at the same concentrations.
体内研究
(In Vivo)

VEGFR2-IN-84 (E20) (50 mg/kg;灌胃;每日一次;21 天) 在雄性 BALB/c 裸鼠 HepG2 肝癌异种移植模型中,显著抑制肿瘤生长,优于同剂量 Lenvatinib (MS-K83330),且无明显体重下降。
VEGFR2-IN-84 (30-60 mg/kg;灌胃;每日一次;20-30 天) 在雄性 BALB/c 裸鼠 A549 肺癌、786-O 肾细胞癌、8305C 甲状腺癌异种移植模型中,分别剂量依赖性抑制肿瘤生长,均优于同剂量 Lenvatinib。
VEGFR2-IN-84 (2 mg/kg;尾静脉注射;单次;24 h) 在健康 ICR 小鼠中具有中等消除半衰期 (T1/2=5.05 h) 和血浆暴露量 (AUC0-∞=1970 ng?h/mL)。

Animal Model: Male BALB/c nude mice (4-5 weeks old, 15-17 g), HepG2 hepatocellular carcinoma subcutaneous xenograft model
Dosage: 50 mg/kg
Administration: Intragastric (p.o.) administration, once daily (qd)
Result: Significantly inhibited the growth of HepG2 xenografts with a tumor growth inhibition (TGI) rate of 94.3%, which was superior to lenvatinib (TGI=83.6%) at the same dose.
No significant body weight loss or overt signs of toxicity were observed throughout the experimental period.
Animal Model: Male BALB/c nude mice (4-5 weeks old, 15-17 g), A549 non-small cell lung cancer subcutaneous xenograft model
Dosage: 30 mg/kg or 60 mg/kg
Administration: Intragastric (p.o.) administration, once daily (qd)
Result: Exhibited dose-dependent antitumor activity.
At 30 mg/kg, the TGI rate was 76.9%, which was superior to lenvatinib (TGI=61.3%) at the same dose.
At 60 mg/kg, achieved a TGI rate of 95.7%, significantly outperforming lenvatinib (TGI=84.6%).
No significant body weight loss was observed.

化学信息

分子量 470.50
分子式 C25H18N4O4S
CAS No. 861877-12-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础